Cellivery Presents COVID-19 Therapeutics Development Status at Bio Korea Special Session

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 20th that it participated as a presenter in the special session on the novel coronavirus infection (COVID-19) at 'BIO KOREA 2020,' the largest domestic bio-industry event hosted by the Korea Health Industry Development Institute, held for a total of six days from the 18th to the 23rd.

This BIO KOREA 2020 is being conducted online. This is due to the global spread of COVID-19. The organizers have created a separate COVID-19 special session and are conducting it as an e-conference accordingly.

The presentation on 'iCP-NI, a novel drug for severe sepsis by suppressing cytokine storm' was directly conducted by Daewoong Cho, CEO of Cellivery. From 9 a.m. on the day until 6 p.m. on the 23rd, it was open on the BIO KOREA homepage under the 'COVID-19 Therapeutics Development Trends Session' with the title ‘Development of iCP-NI Therapeutics for Suppression of Acute Inflammation in COVID-19.’

The presentation topic related to COVID-19 therapeutic development was 'Intracellular delivery of Nuclear Localization Signal regulates the expression of cytokines and chemokines to suppress inflammatory responses.'

A company official stated, "We present the theoretical background and mechanism of action of iCP-NI, which is on the verge of clinical trials by the US FDA as a treatment for COVID-19, along with its therapeutic efficacy in virus-infected animal models and animal models of pulmonary fibrosis and acute pneumonia," adding, "We suggest the development potential of iCP-NI as a COVID-19 therapeutic."

This content was produced with the assistance of AI translation services.